rethinkTHC Search
Menu
Study breakdown

Medical cannabis authorization did not significantly reduce opioid prescribing in a university pain clinic

Retrospective CohortPreliminary evidence
The takeaway

In a retrospective analysis of a university pain clinic, patients who received medical cannabis authorization showed a non-significant 14 mg/day decrease in opioid milligram equivalents, while long-term opioid users maintained doses 63 mg/day higher than other patients regardless of cannabis status.

Chronic pain patients, pain management clinicians, and policymakers evaluating opioid-sparing claims of medical cannabis.

Non-significant 14 mg/day opioid decrease with cannabis authorization; long-term opioid status was the dominant predictor

What the researchers found

Average opioid dose at the final time point was 33.4 mg/day OME overall. Medical cannabis authorization predicted a non-significant decrease of 14.25 mg/day OME. No significant difference between cannabis-authorized (38.51 mg/day) and non-authorized patients (32.60 mg/day). Long-term opioid users had significantly higher OME (85.34 mg/day, 63 mg/day higher than the rest, p<0.0001).

Why it matters

Claims that medical cannabis reduces opioid use are central to many advocacy and policy arguments. This real-world clinical data from a pain specialty setting shows no statistically significant opioid-sparing effect, tempering expectations while not ruling out a modest benefit.

The numbers in context

Overall average OME: 33.4 mg/day. Cannabis-authorized: 38.51 mg/day. Non-authorized: 32.60 mg/day (NS difference). Cannabis consultation: -14.25 mg/day (NS). Long-term opioid code: 85.34 mg/day (63 mg higher, p<0.0001). Overall OME trend: +0.45 mg/day per quarter (NS).

How the study worked

Longitudinal retrospective cohort analysis of electronic health records from a university-based pain clinic, July 2016 to August 2019. Longitudinal multilevel modeling with maximum likelihood estimation compared opioid milligram equivalents over time between patients with and without medical cannabis authorization.

What this study cannot tell us

Retrospective design with no randomization. Patients who sought cannabis authorization may differ from those who did not. Cannabis use was captured by authorization, not actual consumption. The 3-year study period may be too short. A university pain clinic population may not represent all chronic pain patients.

How to read the evidence

Longitudinal retrospective cohort with multilevel modeling from a single academic center, limited by observational design and authorization-as-proxy for use.

When this study was published

Published in 2026, using 2016-2019 health records.

The bigger picture

The null finding joins a growing body of clinical studies showing that population-level claims about cannabis replacing opioids are not consistently supported by individual-level data. The dominant predictor of high opioid use was having a long-term opioid use diagnosis, not cannabis access, suggesting that the opioid problem is driven by factors that cannabis alone cannot address.

Questions still open

  • Would a prospective randomized trial of cannabis for opioid tapering show different results? Are there subgroups of pain patients for whom cannabis does reduce opioid needs? Does the type of cannabis product matter for opioid-sparing effects?

Common questions

Does medical cannabis reduce opioid use?
In this pain clinic study, cannabis authorization was associated with a 14 mg/day decrease in opioid doses, but this did not reach statistical significance. The study cannot confirm that cannabis reduces opioid prescribing.
What was the strongest predictor of high opioid use?
Having a long-term opioid use diagnostic code, which was associated with 63 mg/day higher opioid doses, far exceeding any effect of cannabis authorization.

Read the original research

Medical cannabis authorization and opioid milligram equivalents over time in patients with chronic pain: a retrospective analysis.

Pain medicine (Malden, Mass.), 27(2), 127-135

Citation

Sexton, Michelle; Glodosky, Nicholas C; Cleveland, Michael; Cuttler, Carrie; Lee, Euyhyun; Polston, Gregory R; Furnish, Timothy; Lerman, Imanuel; Schuster, Nathaniel M; Wallace, Mark S. (2026). Medical cannabis authorization and opioid milligram equivalents over time in patients with chronic pain: a retrospective analysis.. Pain medicine (Malden, Mass.), 27(2), 127-135. https://doi.org/10.1093/pm/pnaf113

Explore the wider topic